26 related articles for article (PubMed ID: 29387963)
1. Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer.
Inoue H; Todaka A; Yamazaki K; Fushiki K; Shirasu H; Kawakami T; Tsushima T; Hamauchi S; Yokota T; Machida N; Fukutomi A; Onozawa Y; Andoh A; Yasui H
Invest New Drugs; 2021 Oct; 39(5):1399-1404. PubMed ID: 33835357
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer.
Uwagawa T; Sakamoto T; Gocho T; Shiba H; Onda S; Yasuda J; Shirai Y; Hamura R; Furukawa K; Yanaga K; Ikegami T
PLoS One; 2022; 17(5):e0267623. PubMed ID: 35544539
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
[TBL] [Abstract][Full Text] [Related]
5. Present status and perspective of perioperative chemotherapy for patients with resectable pancreatic cancer in Japan.
Yamada Y
Glob Health Med; 2022 Feb; 4(1):14-20. PubMed ID: 35291202
[TBL] [Abstract][Full Text] [Related]
6. Pathological complete response in a patient with locally advanced pancreatic adenocarcinoma treated with neoadjuvant gemcitabine and S-1: a case report and literature review.
Hua S; Gao J; Xu Q; Hong X; Wu W
Gland Surg; 2022 Feb; 11(2):494-503. PubMed ID: 35284319
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Li D; Chen C; Zhou Y; Chen R; Fan X; Bi Z; Li Z; Liu Y
Medicine (Baltimore); 2015 Sep; 94(35):e1345. PubMed ID: 26334891
[TBL] [Abstract][Full Text] [Related]
9. A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
Oh DY; Cha Y; Choi IS; Yoon SY; Choi IK; Kim JH; Oh SC; Kim CD; Kim JS; Bang YJ; Kim YH
Cancer Chemother Pharmacol; 2010 Feb; 65(3):527-36. PubMed ID: 19578850
[TBL] [Abstract][Full Text] [Related]
10. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
[TBL] [Abstract][Full Text] [Related]
11. Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.
Ueno H; Okusaka T; Furuse J; Yamao K; Funakoshi A; Boku N; Ohkawa S; Yokosuka O; Tanaka K; Moriyasu F; Nakamori S; Sato T
Jpn J Clin Oncol; 2011 Aug; 41(8):953-8. PubMed ID: 21715364
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
Cao C; Kuang M; Xu W; Zhang X; Chen J; Tang C
Jpn J Clin Oncol; 2015 Dec; 45(12):1122-30. PubMed ID: 26518328
[TBL] [Abstract][Full Text] [Related]
13. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer.
Okusaka T; Miyakawa H; Fujii H; Nakamori S; Satoh T; Hamamoto Y; Ito T; Maguchi H; Matsumoto S; Ueno H; Ioka T; Boku N; Egawa S; Hatori T; Furuse J; Mizumoto K; Ohkawa S; Yamaguchi T; Yamao K; Funakoshi A; Chen JS; Cheng AL; Sato A; Ohashi Y; Tanaka M;
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1053-1059. PubMed ID: 28210843
[TBL] [Abstract][Full Text] [Related]
14. S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma.
Winther SB; Bjerregaard JK; Schonnemann KR; Ejlsmark MW; Krogh M; Jensen HA; Pfeiffer P
Cancer Chemother Pharmacol; 2018 Mar; 81(3):573-578. PubMed ID: 29387963
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
